Overview

NTX-301 in MDS/AML

Status:
Recruiting

Trial end date:
2025-03-31

Target enrollment:

Participant gender:

Summary

NTX-301 is a DNMT1 inhibitor. The drug is an oral drug with preclinical data that has shown preclinical anti-leukemic efficacy. This is the first clinical trial using NTX-301 in patients with myeloid malignancies.

Phase:

Phase 1

Details

Lead Sponsor:

University of Alabama at Birmingham